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Abstract
Guanidinoacetic acid (GAA) is the biosynthetic precursor of creatine which is involved in storage and transmission of
phosphate-bound energy. Hepatocytes readily convert GAA to creatine, raising the possibility that the active uptake of GAA
by hepatocytes is a regulatory factor. The purpose of this study is to investigate and identify the transporter responsible for
GAA uptake by hepatocytes. The characteristics of [
14C]GAA uptake by hepatocytes were elucidated using the in vivo liver
uptake method, freshly isolated rat hepatocytes, an expression system of Xenopus laevis oocytes, gene knockdown, and an
immunohistochemical technique. In vivo injection of [
14C]GAA into the rat femoral vein and portal vein results in the rapid
uptake of [
14C]GAA by the liver. The uptake was markedly inhibited by c-aminobutyric acid (GABA) and nipecotinic acid, an
inhibitor of GABA transporters (GATs). The characteristics of Na
+- and Cl
2-dependent [
14C]GAA uptake by freshly isolated rat
hepatocytes were consistent with those of GAT2. The Km value of the GAA uptake (134 mM) was close to that of GAT2-
mediated GAA transport (78.9 mM). GABA caused a marked inhibition with an IC50 value of 8.81 mM. The [
14C]GAA uptake
exhibited a significant reduction corresponding to the reduction in GAT2 protein expression. GAT2 was localized on the
sinusoidal membrane of the hepatocytes predominantly in the periportal region. This distribution pattern was consistent
with that of the creatine biosynthetic enzyme, S-adenosylmethionine:guanidinoacetate N-methyltransferase. GAT2 makes a
major contribution to the sinusoidal GAA uptake by periportal hepatocytes, thus regulating creatine biosynthesis in the
liver.
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Introduction
Guanidinoacetic acid (GAA) is the biosynthetic precursor of
creatine which plays an important role in storage and transmission
of phosphate-bound energy in tissues with high energy demands
[1]. The physiological importance of creatine biosynthesis has
been demonstrated by an inherited deficiency of the creatine
biosynthetic enzyme, S-adenosylmethionine:guanidinoacetate N-
methyltransferase (GAMT) [2]. Patients exhibit a severe reduction
in creatine and the simultaneous accumulation of GAA in the
plasma, and brain, thus causing mental retardation, delayed
speech, and epilepsy [3].
The liver is the main organ responsible for creatine biosynthesis.
Indeed, high levels of GAMT mRNA are found in this tissue in
humans and mice [4] and a severe reduction in GAMT activity
has been detected in the liver of patients with GAMT deficiency
[5]. However, the hepatocytes are incapable of the full synthesis of
creatine from arginine and glycine whereas they readily convert
GAA to creatine [6]. It is thus conceivable that GAA needs to be
delivered from the circulating blood to hepatocytes for creatine
synthesis.
We have found that GAA transport is mediated by a creatine
transporter (CRT/Solute carrier SLC6A8) [7] and a taurine
transporter (TauT/SLC6A6) [8]. However, CRT mRNA is not
expressed in the human liver [9]. TauT-knockout mice exhibit
only a 30% reduction in the taurine content of hepatocytes [10].
These lines of evidence prompted us to hypothesize that another
transporter makes a substantial contributor to GAA uptake by
hepatocytes.
Hepatocyte heterogeneity has been proposed in terms of
transport and enzymatic activities [11]. The autoradiographical
pattern of the liver after [
3H]glutamate bolus administration shows
that glutamate is exclusively taken up by pericentral hepatocytes,
independent of the perfusion direction [11]. This is consistent with
the immunohistochemical distribution of glutamine synthetase
[12] which converts glutamate to glutamine. The functional
coupling of glutamate uptake and glutamine synthesis in the
pericentral hepatocytes raises the possibility that the sinusoidal
transport of GAA and creatine synthesis occur in the same
compartment of a particular hepatocyte population.
The purpose of this study is to identify the transporter
responsible for GAA uptake by hepatocytes using a combination
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32557of the in vivo liver uptake method, freshly isolated hepatocytes, an
expression system of Xenopus laevis oocytes, and RNA interference.
The localization of the transporter in the liver was determined by
immunohistochemical analysis.
Materials and Methods
Animals
Adult male Wistar rats (260–280 g) were purchased from Japan
SLC (Hamamatsu, Japan). Mature female Xenopus laevis were
purchased from Kato-S-Science (Chiba, Japan) and maintained in
a controlled environment. All experiments were approved by the
Animal Care Committee, University of Toyama (Protocol#
S2008PHA-1, A2011PHA-15, A2011PHA-16).
Reagents
[1-
14C]Guanidinoacetic acid ([
14C]GAA, 55 mCi/mmol),
[
3H]water (18 mCi/mol), and [4-
14C]creatine ([
14C]creatine,
50 mCi/mmol) were obtained from Moravek Biochemicals (Brea,
CA), Parkin-Elmer Life and Analytical Sciences (Boston, MA), and
American Radiolabeled Chemicals (St. Louis, MO), respectively.
All other chemicals were commercial products of analytical grade.
In vivo blood-to-liver transport of [
14C]GAA after its
femoral vein administration
Rats were anesthetized with an intraperitoneal injection of
pentobarbital (50 mg/kg body weight), and [
14C]GAA (3 mCi per
rat) dissolved in 400 mL extracellular fluid buffer containing (in
mM) 122 NaCl, 25 NaHCO3, 3 KCl, 0.4 K2HPO4, 1.4 CaCl2, 1.2
MgCl2, 10 D-glucose, and 10 HEPES was injected into the
femoral vein. Tissue sampling and determination of radioactivity
were performed according to a previous report [13]. As an index
of the tissue distribution of GAA, the apparent liver-to-plasma
concentration ratio was used. This ratio (mL/g liver) was defined
as the amount of [
14C] per gram liver divided by that per milliliter
plasma, calculated over the time-period of the experiment. The
results were shown as the apparent liver-plasma concentration
ratio (mL/g liver) versus time (min).
In vivo blood-to-liver transport of [
14C]GAA after its portal
vein administration
Rats were anesthetized by intraperitoneal injection of pento-
barbital (50 mg/kg body weight), and their rectal temperatures
were maintained at 37uC using a hot plate. The hepatic artery
was ligated, and 200 mL Ringer’s HEPES buffer (pH 7.4)
containing both 10 mCi [
14C]GAA or [
14C]creatine and
0.5 mCi [
3H]water as a highly diffusible internal reference, was
rapidly injected into the portal vein. Eighteen seconds after
injection, the right major lobe was excised from the liver and
solubilized in Soluen-350 (Parkin-Elmer Life Science). The
radioactivities of
3Ha n d
14C in the liver and the injection
solutions were determined using a liquid scintillation spectropho-
tometer (LSC-5000, Aloka, Tokyo, Japan). LUI is defined in
equation 1, and was determined using equation 2:
LUI~ET=ER ð1Þ
LUI % ðÞ ~ 14C
  3H
 
counts in the liver =
14C
  3H
 
counts in the injection solution
|100
ð2Þ
Here, ET and ER are the fractions of [
14C]GAA or [
14C]creatine
and [
3H]water, respectively, extracted by the liver during a single
pass. The value of ET can be estimated when LUI and ER are
determined experimentally. Because the ER value of [
3H]water is
reported to be 6564% in rats [14], the following equation is
valid:
ET~LUI| 0:65 ðÞ ð 3Þ
The apparent fractional extractions consist of intracellular
uptake, distribution to the interstitial space, and retention in
the vascular space. Therefore, the extravascular extraction of
[
14C]GAA, which reflect only the intracellular uptake, was
obtained as follows:
The extravascular extraction~ ET-Ens ðÞ = 100-Ens ðÞ ð 4Þ
Here, Ens represents the fractional extraction for distribution in
the vascular and extracellular space. In this calculation, we used
the reported Ens value of 1363% for rats [14].
[
14C]GAA uptake by freshly isolated hepatocytes
Rat hepatocytes were isolated by collagenase perfusion and
Percoll isodensity centrifugation as described previously [15]. The
hepatocytes were resuspended in Tyrode buffer containing (in
mM) 137 NaCl, 2.7 KCl, 1.05 MgCl2, 1.8 CaCl2, 12 NaHCO3,
0.4 NaH2PO4, and 5.6 D-glucose. Uptake of [
14C]GAA or
[
14C]creatine by the freshly isolated hepatocytes was examined
according to the methods described previously [16]. In brief, after
centrifugation and aspiration of the buffer, uptake was initiated by
applying 100 mL Tyrode buffer containing [
14C]GAA or [
14C]cre-
atine at 37uC in the presence or absence of inhibitors. Na
+-free
Tyrode buffer was prepared by replacement of NaCl, NaH2PO4
and NaHCO3 with equimolar N-methyl-D-glucamine, KH2PO4,
and KHCO3, respectively. Cl
2-free uptake buffer was prepared by
replacement with equimolar gluconate. After a predetermined
period, uptake was terminated by centrifugation of the solution.
The cells were then solubilized in 1 N NaOH and subsequently
neutralized with 1 N HCl. The cell-associated radioactivity and
protein content were assayed by liquid scintillation spectrometry
and detergent compatible protein assay (a DC protein assay kit,
Bio-Rad, Hercules, CA) with bovine serum albumin as a standard.
Kinetic analyses
The kinetic parameters for GAA uptake by freshly isolated rat
hepatocytes were obtained from equation 5:
V~ Vmax|C ðÞ = KmzC ðÞ ð 5Þ
where V is the uptake rate of GAA, C is the GAA concentration in
the medium, Km is the Michaelis-Menten constant, and Vmax is
the maximum uptake rate. To obtain kinetic parameters, the
equation was fitted using the iterative non-linear least-squares
regression analysis program, MULTI [17].
The median inhibitory concentration (IC50) value of GABA,
taurine and creatine for [
14C]GAA uptake by rat hepatocytes was
estimated from equation 6, using MULTI.
Percentage of control % ðÞ ~
Pminz Pmax-Pmin ðÞ = 1z I ½  =IC50 ðÞ ð 6Þ
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the maximum percentage of control, and the concentration of
inhibitor, respectively.
RNA interference
RNA interference was performed using the BLOCK-iT Pol II
miR RNAi expression kit (Invitrogen, Carlsbad, CA). Short
hairpin RNAs (shRNAs) unrelated to and targeted to the GABA
transporter (GAT) 2/SLC6A13 (Rmi603286, Invitrogen) were
expressed in primary cultured rat hepatocytes by transient
transfection using Lipofectamine 2000 reagent (Invitrogen) as
previously reported [18].
[
14C]GAA and [
14C]creatine uptake by rat GAT2-
expressing Xenopus laevis oocytes
Using T7 RNA polymerase, capped cRNA was transcribed
from NotI-linearized pGEM-HEN containing an open reading
frame of rat GAT2 cDNA. Defolliculated oocytes were injected
with 23 nL water or the capped cRNA (30–50 ng) and incubated
at 18uC in freshly prepared standard oocyte saline solution
containing 100 mM NaCl, 2 mM KCl, 1.8 mM CaCl2,1m M
MgCl2, and 5 mM HEPES, 25 mg/mL gentamycin, 2.5 mM
pyruvate and 1% bovine serum albumin, pH 7.5. The standard
oocyte saline solution used to incubate the oocytes was replaced
with fresh solution daily. Experiments were performed after
incubation for 4 to 6 days. For the uptake study by Xenopus laevis
oocytes, oocytes were preincubated with 500 mL ND96 solution
containing (in mM) 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, and 5
HEPES for 20 min at 20uC before the uptake experiment. The
uptake experiment was initiated by replacing the ND96 solution
with 200 mL of the same solution containing [
14C]GAA (45 mM)
and [
14C]creatine (45 mM). After incubation for a designated time
at 20uC, the uptake was terminated by addition of ice-cold ND96
solution. Oocytes were then washed four times with ice-cold ND96
solution and solubilized in 5% sodium dodecyl sulfate solution,
and the accumulated radioactivity was determined in a liquid
scintillation counter (LSC-5000, Aloka).
Antibody preparation
Polyclonal antibodies to organic anion transporting polypeptide
1a4 (oatp1a4/Slco1a4) and multidrug resistant protein 6 (MRP6/
ABCC6) were raised against amino acid residues 625–661 of rat
oatp1a4 (GenBank accession number: NP_571981) and 1468–
1502 of rat MRP6 (GenBank accession number: NP_112275). The
polypeptides were expressed as glutathione S-transferase (GST)
fusion proteins using the pGEX4T-2 plasmid vector (GE
Healthcare, Chalfont St. Giles, UK). The fusion protein was
purified with glutathione-Sepharose 4B (GE Healthcare), emulsi-
fied with Freund’s complete adjuvant (Difco, Detroit, MI), and
injected subcutaneously into female Hartley guinea-pigs at
intervals of 2 weeks. Two weeks after the sixth injection, affinity-
purified antibodies were prepared, first using protein G-Sepharose
(GE Healthcare) and then using antigen peptides coupled to
cyanogens bromide-activated Sepharose 4B (GE Healthcare). For
the preparation of affinity media, polypeptides free of GST were
obtained by elution of the cleaved polypeptide after in-column
thrombin digestion of fusion proteins bound to glutathione-
Sepharose 4B.
Immunoblotting
Under deep pentobarbital anesthesia (100 mg/kg body weight,
i.p.), rat liver and heart were transcardially perfused with
phosphate-buffered saline (PBS). The tissues were then homoge-
nized using the nitrogen cavitation technique (800 psi, 15 min,
4uC) in buffer with the following composition (in mM): 10 HEPES,
1 EDTA, 1 EGTA, 320 sucrose, 1 phenylmethylsulfonyl fluoride,
and a protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO),
pH 7.4. The homogenates were centrifuged at 10,000 g for
15 min. The supernatant fluids were further centrifuged at
100,000 g for 60 min to obtain a crude membrane fraction from
the pellets. The protein concentration was determined using a DC
protein assay kit (Bio-rad). Protein samples (50 mg per lane) were
fractionated by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis and electroblotted onto a nitrocellulose membrane.
The blotted membrane was incubated with an affinity-purified
antibody to GAT2 (Sigma Aldrich), oatp1a4, and MRP6 at 0.1–
0.5 mg/mL in Tris-buffered saline (TBS; 25 mM Tris-HCl,
pH 8.0 and 125 mM NaCl, pH 7.4) containing 0.1% Tween 20
and 4% skimmed milk for 16 h at 4uC, and visualized with an
enhanced chemiluminescence kit (GE Healthcare).
Immunohistochemistry
Under deep pentobarbital anesthesia (100 mg/kg body weight,
i.p.), the liver of adult rats were obtained after transcardial fixation
with 4% paraformaldehyde in 0.1 M sodium phosphate buffer
(pH 7.4). The liver was immersed in 30% sucrose in 0.1 M sodium
phosphate buffer. Frozen sections (40 mm in thickness) were
prepared on a cryostat (CM1900; Leica, Nussloch, Germany). The
sections were immunoreacted overnight with rabbit antibody to
GAT2 (2 mg/mL, Sigma Aldrich), singly or in combination with
guinea-pig oatp1a4 antibody (1 mg/mL), guinea-pig MRP6
antibody (1 mg/mL) and guinea-pig GAMT antibody (2 mg/mL,
[19]). Subsequently, they were incubated with species-specific
Alexa Fluor 488- (Invitrogen) and Cy3-conjugated secondary
antibodies (Jackson ImmunoResearch, West Grove, PA) for 2 h.
Photographs were taken using a confocal laser scanning micro-
scope (TCS-SP5; Leica).
Statistical analysis
All data except for kinetic parameters are presented as the
mean6SEM. The kinetic parameters are presented as the
mean6SD. An unpaired, two-tailed Student’s t-test was used to
determine the significance of differences between two group
means. One-way analysis of variance followed by the modified
Fisher’s least-squares difference method was used to assess the
statistical significance of differences among means of more than
two groups.
Results
In vivo hepatic uptake of [
14C]GAA and [
14C]creatine
The liver-to-plasma concentration ratio of [
14C]GAA rapidly
increased up to 5 min after its intravenous administration
(Figure 1A). The extravascular extraction of [
14C]GAA after its
bolus injection into the portal vein was estimated to be 18261%,
and this was reduced by increasing the unlabeled GAA
concentration in the injection solution (Figure 1B). Table 1 shows
the inhibition profile of in vivo hepatic uptake of [
14C]GAA. GAA,
GABA, and b-alanine produced a marked inhibition by more than
60% in each case at a concentration of 1 mM whereas taurine at
the same concentration had no significant effect. GAA, GABA, b-
guanidinopropionic acid, and nipecotic acid significantly inhibited
the [
14C]GAA uptake by more than 69% at a concentration of
10 mM. In contrast, taurine, creatine, creatinine, and L-alanine,
each at a concentration of 10 mM, had a much weaker effect or
no effect at all. The hepatic uptake of [
14C]creatine was not
inhibited by unlabeled creatine at concentrations of 10 mM and
Hepatic Guanidinoacetate Uptake via GAT2
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accumulation of [
14C]GAA in the liver is mediated by a carrier
system preferring GABA over taurine and creatine.
Kinetics and characteristics of [
14C]GAA and [
14C]creatine
uptake by freshly isolated rat hepatocytes
[
14C]GAA uptake by hepatocytes exhibited time-dependent
increases up to 5 min (Figure 2A). In contrast, there was no time-
dependent increase in [
14C]creatine uptake by hepatocytes
(Figure 2A). Unlabeled creatine, at a concentration of 10 mM,
did not affect the [
14C]creatine uptake (Figure 2A inset). The
absence of either Na
+ or Cl
2 reduced the [
14C]GAA uptake by
64.4% and 59.7%, respectively (Table 2). The [
14C]GAA uptake
took place in a concentration-dependent manner and consisted of
a single saturable component (Figure 2B). The apparent Km and
Vmax values of the saturable component were 134627 mM and
1.5360.12 nmol/(min?mg protein), respectively. Table 2 shows
the inhibition profile of several compounds, each at a concentra-
tion of 2 mM, on the [
14C]GAA uptake. GABA, b-alanine, GAA,
b-guanidinopropionic acid, guanidinoethansulfonic acid and
nipecotic acid produced a marked inhibition by more than 67%.
In contrast, creatinine, betaine, guanidinosuccinic acid, L-
arginine, L-alanine, and L-serine had much weaker effects.
GABA, taurine, and creatine inhibited the [
14C]GAA uptake in
a concentration-dependent manner with an IC50 value of
8.8161.33 mM, 1.1360.30 mM, and 1.4260.53 mM, respective-
ly (Figure 2C–E). These results indicate that Na
+- and Cl
2-
dependent GAA uptake by hepatocytes is mediated via a carrier
system preferring GABA over taurine and creatine, most probably
GAT. Among the GAT subtypes, GAT2 is predominantly
expressed in rat liver [20]. A previous report has demonstrated
that rat GAT2 was silenced by the expression of shRNA against
rat GAT2 in a primary culture of rat hepatocytes [18]. [
14C]GAA
uptake was reduced by 46.4% in GAT2-silenced hepatocytes
corresponding to the reduction in GAT2 protein (Figure 2F).
Characteristics of [
14C]GAA uptake in rat GAT2-
expressing Xenopus oocytes (GAT2/oocytes)
[
14C]GAA uptake by GAT2/oocytes was 433-fold greater than
that by water-injected oocytes whereas [
14C]creatine uptake by
GAT2/oocytes was 28-fold higher than in water-injected oocytes
(Figure 3A). The [
14C]GAA uptake by GAT2/oocytes exhibited a
time-dependent increase, and the uptake in these oocytes was
several-fold higher than in water-injected oocytes (Figure 3B). The
GAA uptake by GAT2/oocytes exhibited saturable kinetics with a
Km of 78.9626.4 mM and a Vmax of 193632 pmol/(h?oocyte)
(Figure 3C). The inhibitory effects of GAT substrates and
inhibitors on the [
14C]GAA uptake were further examined
Figure 1. In vivo blood-to-liver transport of GAA. (A) [
14C]GAA uptake by the liver after its intravenous administration. Each point represents the
mean6SEM (n=5–7). (B) Concentration-dependent uptake of GAA by rat liver after its injection into the portal vein. The extravascular extraction of
[
14C]GAA was plotted against the concentration of unlabeled GAA in the injection solution. Each point represents the mean6SEM (n=3–4). (C)
Simultaneous injection of unlabeled creatine had no effect on [
14C]creatine uptake by the liver. Each column represents the mean6SEM (n=5–6).
doi:10.1371/journal.pone.0032557.g001
Table 1. Effect of several compounds on in vivo [
14C]GAA
uptake by rat liver.
Inhibitors
Concentration of each
inhibitor (mM) % of control
Control 10069
Guanidinoacetic acid (GAA) 1 39.462.9*
10 29.462.8*
GABA 1 30.563.6*
10 31.062.4*
b-Alanine 1 41.6612.3*
Taurine 1 87.963.2
10 63.968.7**
b-Guanidinopropionic acid 10 26.563.0*
Nipecotic acid 10 28.662.7*
Creatine 10 73.564.2**
Creatine and Taurine 10 and 10 35.767.6*
Creatinine 10 120619
L-Alanine 10 121621
Inhibitors dissolved in Ringer’s HEPES buffer (pH 7.4) at the indicated
concentrations were injected simultaneously with [
14C]GAA (45 mM) into the rat
portal vein. Each value represents the mean6SEM (n=3–19).
*p,0.01,
**p,0.05, significantly different from the control.
doi:10.1371/journal.pone.0032557.t001
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butyric acid, and b-guanidinopropionic acid exhibited a marked
inhibition of over 95%, each at a concentration of 5–10 mM.
Nipecotic acid, taurine, guanidinoethansulfonic acid, and creatine
inhibited the [
14C]GAA uptake by more than 42%, each at a
concentration of 5 mM. In contrast, creatinine, methlguanidine,
guanidinosuccinic acid, betaine, L-alanine, homovanilic acid, and
L-arginine did not produce any significant inhibition.
Expression and localization of GAT2 in rat liver
Using immunoblotting with the crude membrane fraction from
rat liver, the antibodies to GAT2, oatp1a4, and MRP6 recognized
a single band at 70 kDa, 92 kDa, 178 kDa, respectively
(Figure 4A). The size of each band detected was consistent with
the previous results [21,22]. On the other hand, no band was
detected in rat heart used as negative control for oatp1a4 and
MRP6 expression (Figure 4A). Therefore, the antibodies to GAT2,
Figure 2. Characteristics of [
14C]GAA uptake by freshly isolated rat hepatocytes. (A) Time-course of [
14C]GAA (18 mM) uptake (open circle)
and [
14C]creatine (30 mM) uptake (closed circle) by hepatocytes. Inset graph shows no effect of unlabeled creatine (10 mM) on the [
14C]creatine
uptake at 2 min. Each point represents the mean6SEM (n=3–4). (B) Concentration-dependence of GAA uptake by hepatocytes. The uptake was
measured at the indicated concentration for 3 min. Each point represents the mean6SEM (n=4). (C–E) Inhibitory effect of GABA (C), taurine (D), and
creatine (E) on [
14C]GAA uptake by freshly isolated rat hepatocytes. [
14C]GAA (18 mM) uptake for 3 min at 37uC was measured in the presence and
absence (control) of each compound at the designated concentrations. Each point represents the mean6SEM (n=3–4). (F) Effect of treatment of
shRNA, unrelated or targeted to GAT2, for 24 h on [
14C]GAA (18 mM) uptake by primary cultures of rat hepatocytes at 37uC for 3 min. Immunoblotting
(inset) with antibodies to GAT2 and Na
+,K
+-ATPase used as an internal standard shows the reduction of GAT2 protein expression in GAT2-silenced
hepatocytes. Each column represents the mean6SEM (n=4). *p,0.01, significantly different from the control.
doi:10.1371/journal.pone.0032557.g002
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antibody predominantly labeled hepatocytes in the periportal
region rather than pericentral region (Figure 4B). The intense
signals of GAMT were also distributed predominantly in the
periportal region than in the pericentral region (Figure 4C). In
contrast, the reverse was found for the distribution patterns of
GAT2 and oatp1a4: oatp1a4 was predominantly distributed in the
pericentral region (Figure 4D–E). The immunoreactivities of
GAT2 were partially overlapped with those of oatp1a4 which is
localized on the sinusoidal membrane in the liver (Figure 4E3
inset). The immunostaining of rat GAT2 was localized on the
plasma membrane of hepatocytes which express GAMT
(Figure 4F). Using double immunofluorescence for MRP6, a
marker of the lateral membrane of hepatocytes, the GAT2
immunoreactivities did not overlap with those of MRP6
(Figure 4G). These results indicate that GAT2 is preferentially
localized on the sinusoidal membrane of hepatocytes in the
periportal region.
Discussion
The present study demonstrates that GAT2 is responsible for
the rapid uptake of GAA on the sinusoidal membrane of
hepatocytes predominantly in the periportal region.
In vivo bolus injection of [
14C]GAA into the rat femoral vein or
portal vein results in its rapid extraction by the liver (Figure 1A
and B). Considering that the GAA concentration in the central
vein is lower than that in the hepatic artery and portal vein [6], the
Figure 3. Characteristics of GAA transport in Xenopus laevis
oocytes expressing GAT2 (GAT2/oocytes). (A) Uptake of [
14C]GAA
(45 mM), and [
14C]creatine (45 mM) by oocytes injected with water
(Water; open column) and GAT2 cRNA (GAT2; closed column) for 1 h at
20uC. Each column represents the mean6SEM (n=8–14). *p,0.01,
significantly different from the control. (B) Time-courses of [
14C]GAA
uptake (45 mM) by oocytes injected with water (closed circle) and GAT2
cRNA (open circle) at 20uC. The [
14C]GAA uptake was inhibited by
unlabeled GAA (10 mM; open square). Each point represents the
mean6SEM (n=9–15). *p,0.01, significantly different from the control.
(C) Concentration-dependence of [
14C]GAA uptake by GAT2/ooccytes at
20uC. The uptake was measured at the indicated concentration for 1 h.
Each point represents the mean6SEM (n=5–15).
doi:10.1371/journal.pone.0032557.g003
Table 2. Na
+- and Cl
2-dependence and inhibitory effect of
several compounds on [
14C]GAA uptake by freshly isolated rat
hepatocytes.
Conditions/Inhibitors % of control
Na
+- and Cl
—dependence
Control 100612
Na
+-free 35.662.5*
Cl
—free 40.361.6*
Inhibitory effect
Control 10064
Guanidinoacetic acid (GAA) 24.161.1*
GABA 17.161.6*
b-Alanine 28.565.5*
b-Guanidinopropionic acid 18.960.9*
Guanidinoethansulfonic acid 33.064.4*
Nipecotic acid 30.861.2*
Creatinine 75.368.9**
Guanidinosuccinic acid 71.265.1*
Betaine 64.468.7*
L-Arginine 74.9611.1*
Glycine 54.4611.2*
L-Alanine 59.667.8*
L-Serine 83.866.4
[
14C]GAA (18 mM) uptake by hepetocytes was measured at 37uC for 3 min in the
absence or presence (control) of Na
+ and Cl
2 or in the absence (control) or
presence of inhibitors (2 mM). Each value represents the mean6SEM (n=3–4).
*p,0.01,
**p,0.05, significantly different from the control.
doi:10.1371/journal.pone.0032557.t002
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circulating blood. Since GABA and GAT inhibitors, such as
b-guanidinopropionic acid and nipecotinic acid, produce a
marked inhibition (Table 1), an isoform of GATs is most likely
involved in the GAA uptake by the liver. Furthermore, the
degree of inhibition by b-alanine is comparable with that by
GAA and GABA, each at a concentration of 1 mM (Table 1),
suggesting that GAA, GABA and b-alanine share a common
transport system in the liver. Previous reports have demonstrat-
ed that GAT2 mediates the uptake of b-alanine and its analog
a-fluoro-b-alanine by rat hepatocyets [23] and that a-fluoro-b-
alanine rapidly accumulates in the rat liver after its intravenous
administration [24]. It thus appears that the rapid uptake of
[
14C]GAA by the liver is also mediated by GAT2. In support of
this notion, the characteristics of Na
+-a n dC l
2-dependent
[
14C]GAA uptake by freshly isolated rat hepatocytes (Figure 2
and Table 2) support the hypothesis that GAT2 plays a major
role in GAA uptake by hepatocytes, especially based on the
following evidence. (i) The Km value (134 mM; Figure 2B) and
the inhibition profile (Table 2) of the [
14C]GAA uptake is in
good agreement with those of GAT2-mediated GAA transport
(Figure 3C and Table 3). (ii) GABA causes a marked reduction
in the [
14C]GAA uptake with the lowest IC50 value (Figure 2C).
(iii) [
14C]GAA uptake exhibits a significant reduction corre-
sponding to the decrease in the protein expression of GAT2
(Figure 2F). The Na
+-dependence (64.4%; Table 2) of the
[
14C]GAA uptake is almost identical to the degree of inhibition
by 2 mM GABA (approximately 80%; Table 2). Therefore,
GAT2 would make at least a 64.4% contribution to the total
[
14C]GAA uptake by hepatocytes.
The freshly isolated rat hepatocytes have much higher GAA
uptake activity compared with creatine uptake (Figure 2A) whereas
the liver concentration of creatine is 100-to-680-fold greater than
that of GAA in humans and rats [25]. This confirms the belief that
GAA is readily converted to creatine [6] as soon as GAA is taken
up by hepatocytes. Immunohistochemical analysis reveals that
GAT2 is localized on the sinusoidal membrane of hepatocytes
predominantly in the periportal region (Figure 4). This distribution
pattern is in good agreement with that of GAMT, the creatine
synthetic enzyme (Figure 4). The functional coupling between
GAT2 and GAMT suggests that the supplying pathway for GAA
regulates creatine synthesis in periportal hepatocytes.
It has become evident that hepatocytes located at different
distances from the portal spaces exhibit different transport
characteristics. This includes the preferential uptake of glutamate
[11] and taurocholate [26] by pericentral and periportal
hepatocytes, respectively, after injection into the portal vein.
However, only a limited number of studies have addressed the
question as to whether this heterogeneity is merely due to the
location of hepatocytes or to intrinsic differences between the cells.
The present study provides evidence to support the hypothesis that
GAT2 is responsible for the periportal region-predominant uptake
of GAA by GAMT-expressing hepatocytes and supports the latter
concept. This zonal arrangement for creatine synthesis in the liver
may explain the discrepancy that although the GAA biosynthetic
enzyme, L-arginine:glycine amidinotransferase (AGAT), is ex-
pressed predominantly in pericentral hepatocytes [27], the
hepatocytes are incapable of the full synthesis of creatine from
arginine and glycine [6].
GAT2 mediates the hepatic uptake of GABA, b-alanine, and c-
butyrobetaine, a synthetic precursor of carnitine, with the Km
values of 9–35.3 mM [18,23]. Since the blood concentrations of
GABA (0.13 mM; [28]), b-alanine (,0.5 mM; [29]), and c-
butyrobetaine (0.84–0.95 mM; [30]) are smaller than the Km
value of GAT2-mediated transport for each substrate, GAT2 in
the hepatocytes would not be fully saturated by endogenous
substrates of GAT2 under physiological conditions. The GAA
uptake by rat hepatocytes with a Km value of 134 mM (Figure 2)
would operate at only a small fraction of its maximal activity at a
plasma concentration of 3.73 mM [25]. However, such a transport
system would be relevant for GAA with fluctuations in its plasma
concentration. Creatine supplementation decreases the blood
concentration of GAA due to the downregulation of AGAT
activity in the kidney [6]. Since excess creatine does not alter
GAMT activity in the liver [6], the decrease in GAT2-mediated
GAA uptake by hepatocytes results in the reduction of creatine
biosynthesis in the liver. Patients with GAMT deficiency exhibit a
marked reduction in creatine and a simultaneous accumulation of
GAA (12.9–20.7 mM; [31]) in the circulating blood. Although oral
treatment with creatine increases its plasma concentration above
the normal range (270–763 mM), the problem is that the GAA
concentration in the plasma remains elevated [31]. The present
study indicates that creatine affects GAA uptake by hepatocytes
and GAT2-mediated GAA transport (Figures 2E and 3A, and
Tables 2 and 3), implying that the hepatic clearance of GAA from
the circulating blood is disturbed by increased levels of creatine.
Therefore, monitoring the creatine concentration in the plasma
will be beneficial to ensure that the plasma level of creatine will not
exceed the normal range.
The liver does not express any isoforms of creatine kinases
[32,33] and a carrier system for creatine uptake (Figures 1C and
2). This implies that creatine produced in hepatocytes is released
into the blood stream. Nevertheless, the creatine level in the liver
remains higher than that in the blood [25], raising the possibility
that the liver serves as the storage compartment for creatine. It is
thus intriguing to pursue the mechanism(s) of the continuous
release or stimuli-dependent release of creatine from hepatocytes.
Table 3. Effect of several compounds on [
14C]GAA uptake by
Xenopus laevis oocytes expressing rat GAT2 (GAT2/oocytes).
Inhibitors % of control
Control 10067
GABA 1.7460.44*
b-Alanine 3.5460.64*
b-Guanidinopropionic acid 0.8160.07*
c-Guanidinobutyric acid 2.3560.23*
Taurine 16.664.4*
Guanidinoethansulfonic acid 11.061.2*
Nipecotic acid 11.961.5*
Creatine 57.368.3**
Creatinine 147618
Methlguanidine 131617
Guanidinosuccinic acid 148611
Betaine 96.767.4
L-Alanine 138618
Homovanilic acid 85.367.0
L-Arginine 137615
[
14C]GAA (45 mM) uptake by GAT2/oocytes was measured at 20uC for 1 h in the
absence (control) and presence of inhibitors (5 mM). Each value represents the
mean6SEM (n=10–15).
*p,0.01,
**p,0.05, significantly different from the control.
doi:10.1371/journal.pone.0032557.t003
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32557Figure 4. Expression and localization of GAT2 in rat liver. Red and green fluorescence is defined at the lower left corner of each panel. (A)
Immunoblot of GAT2, oatp1a4, and MRP6 in rat liver and heart. Rat heart was used as negative control for oatp1a4 and MRP6 expression. The size of
the marker proteins is indicated to the left. (B–C) Preferential distribution of GAT2 (B and C) and GAMT (C) in hepatocytes around the portal vein. (D–
E) Distribution of GAT2 and oatp1a4 in the liver. E3 inset: Localization of GAT2 on the oatp1a4-positive sinusoidal membrane (arrowheads). (F) Plasma
membrane localization of GAT2 in GAMT-positive hepatocytes. (G) Double immunofluorescence of GAT2 and MRP6, a marker of the lateral membrane
of hepatocytes. Arrowheads indicate the bile canaliculus. Nuclei were stained with 49,6-diamidino-2-phenylindole (DAPI, blue). In B–E, single (*) and
double (**) asterisks indicate the portal spaces and the central vein, respectively. Scale bars: B–D, 100 mm; E–G, 10 mm.
doi:10.1371/journal.pone.0032557.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32557In conclusion, GAT2 makes a major contribution to GAA
uptake by periportal hepatocytes on the sinusoidal membrane.
The present findings shed light on a regulatory system for creatine
biosynthesis and a functional heterogeneity of hepatocytes.
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